Rodríguez-Reyes ER, Cerda-Flores RM, Quiñones-Pérez JM, Cortés-Gutiérrez EI

Language: Spanish
References: 30
Page: 267-272
PDF size: 106.26 Kb.

ABSTRACT

Objective: to evaluate the validity (sensitivity, specificity, and accuracy) of three screening methods used in the early detection of the cervical carcinoma versus the histopathology diagnosis.
Methods: a selected sample of 107 women attended in the Opportune Detection of Cervicouterine Cancer Program in the Hospital de Zona 46, Instituto Mexicano del Seguro Social in Durango, during the 2003 was included. The application of Papanicolaou, acetic acid test, and molecular detection of human papillomavirus, and histopatholgy diagnosis were performed in all the patients at the time of the gynecological exam. The detection and tipification of the human papillomavirus was performed by polymerase chain reaction (PCR) and analysis of polymorphisms of length of restriction fragments (RFLP). Histopathology diagnosis was considered the gold standard. The evaluation of the validity was carried out by the Bayesian method for diagnosis test.
Results: the positive cases for acetic acid test, Papanicolaou, and PCR were 47, 22, and 19. The accuracy values were 0.70, 0.80 y 0.99, respectively.
Conclusion: since the molecular method showed a greater validity in the early detection of the cervical carcinoma we considered of vital importance its implementation in suitable programs of Opportune Detection of Cervicouterino Cancer Program in Mexico. However, in order to validate this conclusion, cross-sectional studies in different region of country must be carried out.

REFERENCES

1. Salmerón-Castro J, Franco-Marina F, Salazar-Martínez E, Lazcano-Ponce EC. Panorama epidemiológico de la mortalidad por cáncer en el Instituto Mexicano del Seguro Social: 1991-1995. Salud Publica Mex 1997;39(4):266-273.

2. Rivera R, Aguilera J, Larrain A. Epidemiología del virus de papiloma humano. Rev Chil Obstet Ginecol 2002;(67)60:501-506.

3. Moscicki B. VPH y la mujer adolescente. HVP Today 2004;5:8-10.

4. Kuhn L, Denny L, Pollack A, Lorincz A, Richart RM, Wright TC. Human papillomavirus DNA testing for cervical cancer screening in low resource settings. J Natl Cancer Inst 2000;92(10);818-825.

5. Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, et al. The International Biological Study on Cervical Cancer Study Group: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995;87 (11):796-802.

6. Elwood M. Critical appraisals of epidemiological studies and clinical trials. UK: Oxford University Press; 1998. p. 107-113.

7. Fletcher RH, Fletcher SW, Wagner EH. Prevention. En: Fletcher RH, Flecher SW, Wagner EH, editors. Clinical epidemiology. Second edition. Baltimore: Williams & Wilkins; 1996. p. 165-185.

8. Bednov YM, Brosky KR, Sidawy MK. Comparison of the efficacy of the Thinprep method with the conventional cervical smear. Lab Invest 1998;78 (1):36-38.

9. Denny L, Kuhn L, Pollack A, Wainwright H, Wright TC Jr. Evaluation of alternative methods of cervical cancer screening for resource-poor settings. Cancer 2000;89(4):826-33.

10. Maddox P, Szarewski A, Cuzick J. Cytokeratin expression and acetowhite change in cervical epithelium. J Clin Pathol 1994;47(1):15-17.

11. Rodríguez-Reyes ER, Cerda-Flores RM, Quiñones-Pérez JM, Velazco-Rodríguez V, Cortés- Gutiérrez EI. Acetic acid test: a promising screening test for early detection of cervical cancer. Anal Quant Cytol Histol 2002;24(3):134-136.

12. García-Carranca A, Gariglio P. Aspectos moleculares de los papilomavirus humanos y su relación con el cáncer cérvico-uterino. Rev Invest Clin 1993;45(1):85-92.

13. Leal-Garza CH, Cortés-Gutiérrez EI. Detección molecular del virus del papiloma humano en mujeres con cáncer cervicouterino. Gac Med Mex 1996;132(3):295-318.

14. Megevand E, Denny L, Dehaeck K, Soeters R, Bloch B. Acetic acid visualization of the cervix: An alternative to cytologic screening. Obstet Gynecol 1996;88(3):383-386.

15. Walter P, Dexeus S, de Palo G, Barrasso R, Campion M, Girardi F, et al . International terminology of colposcopy: an updated report from the International Federation for cervical pathology and colposcopy. Obstet Gynecol 2003;101(1):175-177.

16. Lundberg GO. The 1988 Bethesda system for reporting cervical/vaginal cytological diagnoses. JAMA 1989;262(7):931.

17. Reid R. Preinvasive disease. En: Berek J, Hacker NF, editors. Practical gynecologic oncology. Baltimore: Williams and Wilkins; 1989. p. 199.

18. Creasman W. New gynecologic cancer staining. Obstet Gynecol 1990;75(2):287-288.

19. Bauer H, Greer C, Manos M. Detection of human papillomavirus infection using PCR. En: Herrington CS, McGee JO’D, editors. Diagnostic molecular pathology: a practical approach. Oxford, UK: Oxford Univ Press; 1992. p. 131-152.

20. Lie AK, Skjeldestad FE, Hagen B, Johannessen E, Skarsvag S, Haugen A. Comparison of light microscopy, in situ hybridization and polymerase chain reaction for detection of human papillomavirus in histological tissue of cervical intraepithelial neoplasia. APMIS 1997;105(2):115-120.

21. Gjoen K, Sauer T, Olsen AO, Orstavik I. Correlation between polymerase chain reaction and cervical cytology for detection of human papillomavirus infection in women with and without dysplasia. APMIS 1997;105(1):171-175.

22. Schneider A, Hoyer H, Lotz B, Leistritza S, Kühne- Heid R, Nindl I, Müller B, Haerting J, Dürst M. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer 2000; 89(6):529-534.

23. Blumenthal PD, Gaffikin L, Chirenje ZM, McGrath J, Womack S, Shah K. Adjunctive testing for cervical cancer in low resource settings with visual inspection, HPV, and Pap smear. Int J Gynecol Obstet 2001;72(1):47-53.

24. Lynette D, Kuhn L, Pollack A, Wainwright H, Wright TC. Evaluation of alternative methods of cervical cancer screening for resource-poor settings. Cancer 2000;89(4):826-833.

25. Zazove P, Reed BD, Gregoire L, Ferenczy A, Gorenflo DW, Lancaster WD. Low false negative rate of PCR analysis for detecting human papillomavirus related cervical lesions. J Clin Microbiol 1998;36(9):2708-2713.

26. Anonymous. Development of screening programs in the last 20 years. Interview with Prof Nick Day. HVP Today 2005;6(April):1,3.

27. Anonymous. Interim guidance on the use of HPV testing combined with cytology in primary cervical screening. Interview with Cox Thomas. HVP Today 2005;6(April):4-5.

28. Cortés-Gutiérrez EI, Cerda-Flores RM, Leal-Klevezas DS, Hernández-Garza F, Leal-Garza CH. Validating polymerase chain reaction for detecting HPV in cervical intraepithelial neoplasia. Ann Quant Cytol Histol 2003;25(2):115-118.

29. Mandelblatt JS, Lawrence WF, Gaffikin L, Limpahayom KK, Lumbiganon P, Warakamin S, et al. Cost and benefits of different strategies to screen for cervical cancer in less-developed countries. J Natl Cancer Inst 2002;94:1469-1483.

30. Prevención del cáncer cervicouterino. Alliance for cervical cancer prevention. Disponible en http://www.path.org/files/RH_accp_conclusions_fs_sp.pdf